|
Author:
Date:
2021-04-05
[Abstract] We have demonstrated that a specific population of ginger-derived nanoparticles (GDNP-2) could effectively target the colon, reduce colitis, and alleviate colitis-associated colon cancer. Naturally occurring GDNP-2 contains complex bioactive components, including lipids, proteins, miRNAs, and ginger secondary metabolites (gingerols and shogaols). To construct a nanocarrier that is more clearly defined than GDNP-2, we isolated lipids from GDNP-2 and demonstrated that they could self-assemble into ginger lipid-derived nanoparticles (GLDNP) in an aqueous solution. GLDNP can be used as a nanocarrier to deliver drug candidates such as 6-shogaol or its metabolites (M2 and M13) to the colon. To characterize the nanostructure of GLDNP, our lab extensively used atomic force microscopy (AFM) ...
[摘要] [摘要]我们已经证明，特定人群的生姜纳米颗粒（GDNP-2）可以有效地靶向结肠，减少结肠炎，并减轻结肠炎相关的结肠癌。天然存在的GDNP-2包含复杂的生物活性成分，包括脂质，蛋白质，miRNA和生姜的次生代谢产物（姜油和松香油）。为了构建比GDNP-2更明确定义的纳米载体，我们从GDNP-2中分离出脂质，并证明它们可以自组装成在水溶液中生姜脂质衍生的纳米颗粒（GLD NP ）。GLD NP可用作纳米载体，以将诸如6-shogaol或其代谢产物（M2和M13）之类的药物念珠菌递送至结肠。Ť Ó表征纳米结构GLDNP ，邻乌尔实验室中广泛使用原子力显微镜（AFM）技术作为一种工具 可视化载药的GLDN P的形态。在此，我们提供了一个详细的协议来演示这种过程。
[背景]开发新的基于药物的肠道肠道疾病（IBD）治疗方法必须克服众多挑战，包括潜在的脱靶效应，大规模生产成本以及确保组织特异性递送，全身安全性和低毒性的需求。我们的组和其他最近已经证明，人工合成的纳米颗粒可以定位低剂量的药物（例如，siRNA的，蛋白质，或肽），以结肠组织或结肠免疫细胞，例如巨噬细胞（奥博锐和兰普雷克特，2010 ;陈等人， 2017 ...
|